Pancreatic Cancer Research

ResearcherFujita Health UniversityActive in the last 2 years

Eizaburo Ohno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7730-4630; OpenAlex author ID A5026347742. Sources: OpenAlex.

Their work

Papers
24 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 8 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 24

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Efficacy of 1-Kestose Supplementation in Patients with Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Pilot Study. First author DOI 10.3390/nu16172889↗
  3. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. First author DOI 10.5946/ce.2022.278↗
  4. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less First author DOI 10.21203/rs.3.rs-3014153/v1↗
  5. Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/diagnostics13020215↗
  6. Comparison of contrast-enhanced transabdominal ultrasonography following endoscopic ultrasonography with GD-EOB-DTPA-enhanced MRI for the sequential diagnosis … First author DOI 10.1002/jhbp.1097↗
  7. Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreat… Co-author DOI 10.1007/s00464-021-08981-2↗
  8. Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. Co-author DOI 10.1016/j.jgo.2022.09.005↗
  9. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  10. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  11. Author Correction: Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-022-21219-y↗
  12. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  13. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … Co-author DOI 10.1186/s12885-022-09272-2↗
  14. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. First author DOI 10.1016/j.pan.2020.12.022↗
  15. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-021-86979-5↗
  16. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. Co-author DOI 10.1111/jgh.15163↗
  17. Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography. Co-author DOI 10.1186/s12876-020-01228-9↗
  18. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.1159/000492388↗
  19. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  20. Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. Co-author DOI 10.1111/jgh.13967↗
  21. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-4453-z↗
  22. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. Co-author DOI 10.1111/jgh.13172↗
  23. Treatment with near-infrared radiation promotes apoptosis in pancreatic cancer cells. Co-author DOI 10.3892/ol.2015.3399↗
  24. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-010-1531-6↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuya Ishikawa · 19 shared papers, 2018–2024 · strength 2.33
  2. Hiroki Kawashima · 20 shared papers, 2011–2024 · strength 2.33
  3. Yoshiki Hirooka · 15 shared papers, 2011–2024 · strength 1.53
  4. Tadashi Iida · 11 shared papers, 2020–2024 · strength 1.51
  5. Mitsuhiro Fujishiro · 9 shared papers, 2020–2022 · strength 1.10
  6. Yasuyuki Mizutani · 7 shared papers, 2022–2024 · strength 1.04
  7. Senju Hashimoto · 6 shared papers, 2011–2024 · strength 0.56
  8. Kunio Kataoka · 4 shared papers, 2020–2024 · strength 0.55
  9. Osamu Maeda · 4 shared papers, 2019–2024 · strength 0.54
  10. Masakatsu Yoshikawa · 4 shared papers, 2020–2022 · strength 0.47
  11. Yasuhiro Kodera · 4 shared papers, 2018–2024 · strength 0.47
  12. Junpei Yamaguchi · 3 shared papers, 2019–2024 · strength 0.40
  13. Yukihiro Yokoyama · 3 shared papers, 2019–2024 · strength 0.40
  14. Atsushi Enomoto · 3 shared papers, 2022 · strength 0.38
  15. Kentaro Yamao · 2 shared papers, 2023–2024 · strength 0.36
  16. Kazunori Nakaoka · 2 shared papers, 2023–2024 · strength 0.35
  17. Hidemi Goto · 6 shared papers, 2011–2019 · strength 0.33
  18. Tomoki Ebata · 2 shared papers, 2022–2024 · strength 0.33
  19. Kenta Yamada · 3 shared papers, 2020–2021 · strength 0.31
  20. Shinji Mii · 2 shared papers, 2022 · strength 0.24
  21. Hisashi Haga · 2 shared papers, 2022 · strength 0.24
  22. Atsushi Masamune · 2 shared papers, 2022 · strength 0.24
  23. Yukio Ando · 2 shared papers, 2019–2022 · strength 0.21
  24. Suguru Yamada · 2 shared papers, 2019–2022 · strength 0.21
  25. Tsutomu Fujii · 2 shared papers, 2019–2022 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.